221 related articles for article (PubMed ID: 34530004)
1. Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling.
Guimarães M; Somville P; Vertzoni M; Fotaki N
J Pharm Sci; 2021 Dec; 110(12):3874-3888. PubMed ID: 34530004
[TBL] [Abstract][Full Text] [Related]
2. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
Guimarães M; Vertzoni M; Fotaki N
AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
[TBL] [Abstract][Full Text] [Related]
3. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
[TBL] [Abstract][Full Text] [Related]
4. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups.
Liu XI; van den Anker JN; Burckart GJ; Dallmann A
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S94-S107. PubMed ID: 34185902
[TBL] [Abstract][Full Text] [Related]
6. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
8. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
[TBL] [Abstract][Full Text] [Related]
9. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutic
Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
[TBL] [Abstract][Full Text] [Related]
11. Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states.
Litou C; Patel N; Turner DB; Kostewicz E; Kuentz M; Box KJ; Dressman J
Eur J Pharm Sci; 2019 Oct; 138():105031. PubMed ID: 31386891
[TBL] [Abstract][Full Text] [Related]
12. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
[TBL] [Abstract][Full Text] [Related]
13. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
14. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.
Darwich AS; Margolskee A; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
Eur J Pharm Sci; 2017 Jan; 96():626-642. PubMed ID: 27693299
[TBL] [Abstract][Full Text] [Related]
15. Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process.
Caleffi-Marchesini ER; Herling AA; Macente J; Bonan RH; de Freitas Lima P; Moreno R; Alexandre V; Charbe NB; Borghi-Pangoni FB; Cristofoletti R; Diniz A
CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):208-221. PubMed ID: 37916262
[TBL] [Abstract][Full Text] [Related]
16. Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK®.
Cuquerella-Gilabert M; Reig-López J; Serna J; Rueda-Ferreiro A; Merino-Sanjuan M; Mangas-Sanjuan V; Sánchez-Herrero S
Comput Methods Programs Biomed; 2024 Jan; 243():107929. PubMed ID: 38006685
[TBL] [Abstract][Full Text] [Related]
17. Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro-in vivo correlation.
Golhar A; Pillai M; Dhakne P; Rajput N; Jadav T; Sengupta P
Int J Pharm; 2023 Aug; 643():123267. PubMed ID: 37488057
[TBL] [Abstract][Full Text] [Related]
18. Integrating Forward and Reverse Translation in PBPK Modeling to Predict Food Effect on Oral Absorption of Weakly Basic Drugs.
Franco YL; Da Silva L; Charbe N; Kinvig H; Kim S; Cristofoletti R
Pharm Res; 2023 Feb; 40(2):405-418. PubMed ID: 36788156
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.
Emami Riedmaier A; Lindley DJ; Hall JA; Castleberry S; Slade RT; Stuart P; Carr RA; Borchardt TB; Bow DAJ; Nijsen M
J Pharm Sci; 2018 Jan; 107(1):495-502. PubMed ID: 28993217
[TBL] [Abstract][Full Text] [Related]
20. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]